Strober , B., Asahina, A., Mrowietz, U., Lebwohl, M., Foley, P., Langley, R., Barker, J., Cioffi, C., Cross, N., Wang, M. ., & Paul, C. (2021). Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine, 5(6), s52.